Case 2—volumetric MRI tumour measurements of perihepatic and pelvic mesothelioma demonstrating a 39% reduction in tumour volume after 10 months treatment with apitolisib.
Case series overview: clinical presentation, treatment modality, best tumour marker, radiological response and time to progression*.
*TTP, time to progression; mo, months; SD, stable disease; cPR, confirmed partial response; AWD, alive with disease; RT, radiotherapy; cis, cisplatin; carbo, carboplatin; pem, pemetrexed; PI3K, phosphatidyl-3-kinase; mTOR, mammalian target of rapamycin; PARP, poly(ADP)-ribose polymerase; HDAC, histone deacetylase; NK, not known.
Thank you for your interest in spreading the word on ESMO Open.
NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.